Control of Skeletal Growth by ATF-2
Control of Skeletal Growth by ATF-2
批准号:
7215624
负责人:
PHYLLIS A. LUVALLE
金额:
$27.95万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-04-15 至 2009-03-31
关键词:
Activating Transcription Factor 2AffectApoptosisBone GrowthBone MarrowCartilaginous exostosisCell CycleCell Cycle ProgressionCell Cycle ProteinsChondrocytesChondrogenic NeoplasmCyclic AMP Response ElementCyclin ACyclin D1DNA SequenceDataDefectDegenerative polyarthritisDiseaseDisruptionDwarfismElementsEnd PointEpiphysial cartilageEquilibriumFGFR3 geneFOS geneGene ActivationGene ExpressionGene TargetingGenesGenetic TranscriptionGoalsGrowthHumanHuman GeneticsJUN geneMeasuresMessenger RNAMolecularMusMutationNucleic Acid Regulatory SequencesParathyroid Hormone ReceptorPathway interactionsPhenotypePhosphorylationPlayProliferatingProteinsRBL2 geneRestRetinoblastoma ProteinRoleSignal PathwaySiteSkeletal systemSurvival RateSyndromeThyroid Hormone ReceptorTransforming Growth Factor beta ReceptorsTranslationsVitamin D3 Receptorbcl-1 Genesdesignfetalhuman RBL2 proteinhypochondroplasiapostnatalprotein expressionreceptorskeletal disordertranscription factor
中文摘要
描述(由申请方提供):生长板软骨细胞进展的控制对于适当的骨和骨髓形成至关重要。PTHrP受体、FGFR 3受体、TGF β受体II型、维生素D受体和甲状腺激素受体等几种基因的破坏导致小鼠生长板的解体和异常的软骨内骨化。多种人类遗传性和获得性骨骼疾病是由生长板中软骨细胞增殖和成熟之间的平衡紊乱引起的,包括软骨发育不良、过度生长疾病如Beckwith Wiedernann综合征、骨软骨瘤和其他软骨肿瘤以及某些形式的骨关节炎。转录激活因子2(ATF-2)靶向许多不同基因中的环腺苷酸反应元件(CRE),并导致基因转录的激活。小鼠中ATF-2基因的突变导致生长板软骨细胞中ATF-2的缺失和软骨内骨化缺陷,类似于人软骨发育不全,这是由于FGFR 3受体中的激活突变引起的侏儒症。ATF-2缺陷小鼠的存活率显著降低,并显示出包括增殖区和肥大区减少的生长板表型。该提案的总体目标是确定ATF-2在控制软骨细胞增殖和生长板进展中的作用。该提案的重点是ATF-2的八个基因靶点:细胞周期蛋白D1,细胞周期蛋白A,c-Fos,c-Jun,视网膜母细胞瘤蛋白(pRb),p107,p130和Bcl-2。除Bcl-2外,所有Bcl-2都直接参与细胞周期进程,因此是软骨细胞增殖的调节剂。Bcl-2在细胞凋亡的控制中起作用,细胞凋亡发生在生长板中肥大区的终末软骨细胞中。该提议利用ATF-2缺陷型小鼠的生长板进行以下分子分析:1)ATF-2对靶基因的直接和间接作用; 2)在ATF-2不存在的情况下靶基因表达减少的后果;和3)导致正常或异常生长板软骨细胞增殖和进展的信号传导途径的定义。
英文摘要
DESCRIPTION (provided by applicant): Control of growth plate chondrocyte progression is essential for proper bone and marrow formation. Disruptions in several genes such as those for the PTHrP receptor, FGFR3 receptor, TGF beta receptor type II, vitamin D receptor, and thyroid hormone receptor result in disorganization of the growth plate and abnormal endochondral ossification in mice. Multiple human genetic and acquired skeletal disorders result from the perturbation of the balance between chondrocyte proliferation and maturation in the growth plate, including chondrodysplasias, overgrowth diseases like Beckwith Wiedernann syndrome, osteochondromas and other cartilage neoplasms, and some forms of osteoarthritis. Activating transcription factor 2 (ATF-2) targets the cyclic AMP response element (CRE) in many different genes and results in the activation of gene transcription. A mutation in the ATF-2 gene in mice results in the absence fo ATF-2 in growth plate chondrocytes and defects in endochondral ossification resembling human hypochondroplasia, a dwarfism due to activating mutations in the FGFR3 receptor. ATF-2-deficient mice have a substantially reduced survival rate, and display a growth plate phenotype that encompasses reductions in both the proliferative and hypertrophic zones. The overall goal of this proposal is to define the roles of ATF-2 in control of chondrocyte proliferation and growth plate progression. The proposal is focused on eight gene targets of ATF-2: those for cyclin D1, cyclin A, c-Fos, c-Jun, the retinoblastoma protein (pRb), p107, p130,and Bcl-2. All but Bcl-2 are directly involved in cell cycle progression, and therefore are regulators of chondrocyte proliferation. Bcl-2 plays a role in the control of apoptosis, which occurs in the terminal chondrocytes of the hypertrophic zone in the growth plate. This proposal exploits the growth plates of ATF-2-deficient mice for molecular analyses of 1) the direct and indirect effects of ATF-2 on target genes; 2) the consequences of reductions in expression of the target genes in the absence of ATF-2; and 3) the definition of signaling pathways that result in normal I or abberant growth plate chondrocyte proliferation and progression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Control of Skeletal Growth by ATF-2
-
批准号:7393638
-
项目类别:
-
资助金额:$27.36万
-
财政年份:2004
-
负责人:PHYLLIS A. LUVALLE
-
依托单位:
Control of Skeletal Growth by ATF-2
-
批准号:6777709
-
项目类别:
-
资助金额:$29.5万
-
财政年份:2004
-
负责人:PHYLLIS A. LUVALLE
-
依托单位:
Control of Skeletal Growth by ATF-2
-
批准号:6886808
-
项目类别:
-
资助金额:$29.52万
-
财政年份:2004
-
负责人:PHYLLIS A. LUVALLE
-
依托单位:
Control of Skeletal Growth by ATF-2
-
批准号:7055365
-
项目类别:
-
资助金额:$28.79万
-
财政年份:2004
-
负责人:PHYLLIS A. LUVALLE
-
依托单位:
CELL-SPECIFIC INDUCTION OF TYPE X COLLAGEN EXPRESSION
-
批准号:3031771
-
项目类别:
-
资助金额:$3.05万
-
财政年份:1989
-
负责人:PHYLLIS A. LUVALLE
-
依托单位:
CELL-SPECIFIC INDUCTION OF TYPE X COLLAGEN EXPRESSION
-
批准号:3031769
-
项目类别:
-
资助金额:$2.0万
-
财政年份:1988
-
负责人:PHYLLIS A. LUVALLE
-
依托单位:
CELL-SPECIFIC INDUCTION OF TYPE X COLLAGEN EXPRESSION
-
批准号:3031770
-
项目类别:
-
资助金额:$2.5万
-
财政年份:1988
-
负责人:PHYLLIS A. LUVALLE
-
依托单位:
海外基金